Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Neurol Sci ; 44(12): 4307-4312, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37597088

RESUMO

Anti-NMDA receptor encephalitis (NMDARE), an autoimmune encephalitis associated with autoantibodies against the N-methyl-D-aspartate (NMDA) receptor, affects predominantly young women and is associated with psychiatric symptoms, seizures, movement disorders, and autonomic instability. Traditional treatments of anti-NMDA receptor encephalitis involve corticosteroids, intravenous immunoglobulin, plasmapheresis, cyclophosphamide, and rituximab. However, many controversies remain in the treatment for NMDA receptor encephalitis, such as optimal timing and combination of different immunotherapies, the role of newer strategies (e.g., bortezomib or tocilizumab) for severe and refractory patients, and the need or not for long-term immunosuppression. Our goal was to perform a scoping review to discuss the controversial topics of immunotherapy for NMDA receptor encephalitis and propose operational definitions to guide clinical practice and future research in the field.


Assuntos
Encefalite Antirreceptor de N-Metil-D-Aspartato , Humanos , Feminino , Encefalite Antirreceptor de N-Metil-D-Aspartato/complicações , Receptores de N-Metil-D-Aspartato , Ciclofosfamida/uso terapêutico , Rituximab/uso terapêutico , Autoanticorpos , Imunoterapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA